A study published in Nature Microbiology now shows for the first time that Candida auris uses a CO₂-based metabolic strategy to survive in the nutrient-poor conditions of the skin and to better tolerate antifungal therapies – especially amphotericin B (AMB).24. Dezember 2025
News Paradigm Health Raises $78M & Acquires Flatiron Health’s Clinical Research Business –Healthradar4. Dezember 2025 What You Should Know: – Paradigm Health’s acquisition of Flatiron Health’s Clinical Research Business, coupled with a long-term strategic partnership, marks…
